Oncology scientists with clinical trial experience and an interest in new approaches to developing or enhancing agents for the diagnosis, treatment, and prevention of cancer are invited to attend the 2008 Accelerating Anticancer Agent Development and Validation Workshop. ASCO is co-sponsoring this event with the American Association for Cancer Research (AACR), the Duke Comprehensive Cancer Center, the National Cancer Institute (NCI), and the U.S. Food and Drug Administration (FDA). The workshop will be held in Bethesda, Maryland, at the Bethesda North Marriott Hotel and Conference Center, on June 18-20.
The workshop is designed to bring together leaders in clinical and translational cancer research from academia, industry, NCI, and FDA to assist investigators in understanding and improving the process of cancer drug development. Because the course capacity will be restricted, the event will offer an intimate atmosphere in which participants can bring an agent or strategy with promising early-stage clinical data for discussion. An FDA representative, a biostatistician, and an academic/industrial clinical investigator will be assigned to each small group to discuss development strategies, including potential pitfalls and potential acceptability of the evidence produced to support a new drug application. These small group sessions will be supplemented with lectures, roundtable breakout sessions, and a “One-on-One with the Faculty” session.
Applicants should have at least four years of research experience in cancer drug development-in an academic, industry, or government agency setting-and previous clinical trial experience as a study principal investigator, co-investigator, or participating physician at an approved site. Academic participants should be at the assistant professor level (postdoctoral students and fellows are not eligible) and should have prior or current external, independent funding in support of their research. Industry participants must hold a position on a drug development team. Applicants must supply verification from a supervisor or department/division head that the minimum course requirements have been met and institutional/corporate approval to participate in the workshop has been granted.
As the number of workshop participants will be limited, early enrollment is encouraged. Registration will be closed when course capacity has been reached. Only online applications will be accepted.
More information about the 2008 Accelerating Anticancer Agent Development and Validation Workshop - including a program schedule, faculty list, and logistic details - is available online.
Visit the official 2008 Accelerating Anticancer Agent Development and Validation Workshop website
|
